pioglitazone and fenofibrate
pioglitazone has been researched along with fenofibrate in 68 studies
Research
Studies (68)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 30 (44.12) | 29.6817 |
2010's | 33 (48.53) | 24.3611 |
2020's | 5 (7.35) | 2.80 |
Authors
Authors | Studies |
---|---|
Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Acton, JJ; Akiyama, TE; Berger, JP; Chang, CH; Colwell, L; Debenham, S; Doebber, T; Einstein, M; Liu, K; McCann, ME; Meinke, PT; Moller, DE; Muise, ES; Tan, Y; Thompson, JR; Wong, KK; Wood, HB; Wu, M; Xu, L | 1 |
Akiyama, TE; Berger, JP; Chang, CH; Doebber, TW; Einstein, M; Liu, K; Liu, W; McCann, ME; Meinke, PT; Wood, HB | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y | 1 |
Kimura, H; Momose, Y; Moriyama, S; Odaka, H; Sakamoto, J; Sawada, H; Sugiyama, Y | 1 |
Grüb, M; Hombach, V; Kehrle, B; Koenig, W; Kohlhammer, K; Libby, P; Marx, N; Plutzky, J | 1 |
Jensen, PB; Larsen, LK; Larsen, PJ; Sørensen, RV; Vrang, N; Wassermann, K; Wulff, EM | 1 |
Horiike, N; Iwai, M; Kanno, S; Matsui, H; Matsuura, B; Minami, H; Onji, M; Tsubouchi, E | 1 |
Fang, H; He, YL; Liu, YX; Ye, P; Zhou, X | 1 |
Doweiko, J; Gautam, S; Gavrila, A; Hsu, W; Karchmer, AW; Mantzoros, CS; Martin, L; Moses, AC; Tsiodras, S | 1 |
Cha, JY; Ge, H; Gopal, H; Harp, C; Li, C; Repa, JJ; Yu, X | 1 |
Fiévet, C; Fruchart, JC; Hennuyer, N; Mezdour, H; Staels, B; Tailleux, A; Torpier, G | 1 |
Buechler, C; Kirchner, S; Laberer, S; Neumeier, M; Schäffler, A; Schölmerich, J; Weigert, J; Weiss, T | 1 |
Ruiz, J | 1 |
Albert, AJ; Cong, Z; Gabbay, RA; Gilliland, KL; Liu, W; Mauger, DT; Nelson, AM; Rosamilia, LL; Sivarajah, S; Thiboutot, DM; Trivedi, NR | 1 |
McCance, DR; McMahon, R; Powell, L; Ryan, KE; Trimble, ER | 1 |
Robinson, JG | 1 |
Game, BA; He, L; Huang, Y; London, SD; Lopes-Virella, MF; Maldonado, A; Nareika, A; Sanders, JJ; Slate, EH | 1 |
Bertollo, CM; Coelho, MM; Costa, KA; Nascimento, EB; Oliveira, AC; Rocha, LT | 1 |
Bajaj, M; DeFronzo, RA; Glass, L; Hardies, LJ; Musi, N; Suraamornkul, S | 1 |
Matsui, J; Matsuki, K; Murakami, H; Suda, T; Sugimoto, K; Tamasawa, N; Tanabe, J; Yamashita, M; Yasujima, M | 1 |
Hasegawa, K; Hayashi, K; Homma, K; Ito, O; Kanda, T; Omata, K; Saruta, T; Sugano, N; Tatematsu, S; Wakino, S; Yoshioka, K | 1 |
Koh, KK; Quon, MJ | 1 |
Aslanidis, C; Bauer, S; Buechler, C; Gröschl, B; Hartmann, A; Mages, W; Neumeier, M; Obed, A; Schäffler, A; Schnitzbauer, AA; Schölmerich, J; Weigert, J | 1 |
Harada, H; Hihara, T; Inoue, T; Kasai, S; Matsuura, F; Shinoda, M; Tanaka, I; Yoshitomi, H | 1 |
Dieterich, HA; Dole, WP; Howard, D; Maboudian, M; Vaidyanathan, S; Warren, V; Yeh, CM | 1 |
Cachofeiro, V; Davel, AP; Fukuda, LE; Lahera, V; Lopes, LR; Rossoni, LV; Verissimo-Filho, S | 1 |
Bränström, R; Dey, D; Forsberg, L; Lu, M; Sjöholm, A; Zhang, F; Zhang, Q | 1 |
Boettcher, BR; Gao, J; Gounarides, JS; Laurent, D | 1 |
Akita, N; Fukutomi, T; Gonzalez, FJ; Hossain, MA; Kimura, G; Ogata, M; Staels, B; Suzuki, S; Tsujita, M; Yokoyama, S | 1 |
Campbell, JH; Cullen, B; Daugherty, A; Golledge, J; Moran, CS; Norman, PE; Rush, C; Secomb, E; Wood, F | 1 |
Antonelli, A; Fallahi, P; Ferrannini, E; Ferrari, SM; Frascerra, S; Mancusi, C; Metelli, MR; Orlando, C; Pupilli, C | 1 |
Awori, M; Bauss, F; Bénardeau, A; Samadfam, R; Sebokova, E; Smith, SY; Wright, M | 1 |
Crowe, P; Kankara, C; McCance, DR; McGinty, A; McPeake, J; Powell, LA; Trimble, ER; Young, IS | 1 |
Antonelli, A; Bernini, G; Fallahi, P; Ferrannini, E; Ferrari, SM; Frascerra, S; Gelmini, S; Pupilli, C; Ruffilli, I; Sellari-Franceschini, S | 1 |
Das, SK; Elbein, SC; Kern, PA; Rasouli, N; Sharma, NK | 1 |
Benz, J; Dietz, M; Grether, U; Hartman, P; Kuhn, B; Maerki, HP; Mohr, P; Ruf, A; Wright, MB | 1 |
Blander, G; Bobadilla, M; Catlett, NL; Deehan, R; Edgar, A; Elliston, KO; Haefliger, C; Ladd, W; Maerz-Weiss, P; Mizrahi, J; Steiner, G; Wong, B; Wright, MB | 1 |
Barbieri, M; D'Amico, M; Di Filippo, C; Di Ronza, C; Duan, SZ; Esposito, A; Ferraraccio, F; Marfella, R; Mortensen, RM; Paolisso, G; Rizzo, MR; Rossi, F | 1 |
Dhull, P; Kumar, KV; Patnaik, SK; Upreti, V | 1 |
Chen, M; Deng, D; Fang, Z; Hu, H; Luo, L; Wang, Y; Xu, M | 1 |
Budhiraja, RD; Grover, S; Kumar, P; Singh, K; Vikram, V | 1 |
Jouzeau, JY; Koufany, M; Moulin, D | 1 |
Barbiero, JK; da Cunha, C; da Silva Fernandes, MJ; Lima, MM; Lucio Boschen, S; Persike, DS; Santiago, RM; Tonin, FS; Vital, MA | 1 |
Benavidez, JM; Black, M; Blednov, YA; Edenberg, HJ; Ferguson, LB; Foroud, T; Goate, AM; Harris, RA; Hesselbrock, V; Schoenhard, GL; Wetherill, L | 1 |
Awori, M; Bauss, F; Bénardeau, A; Chouinard, L; Guldberg, RE; Samadfam, R; Sebokova, E; Smith, SY; Wright, MB | 1 |
Abd El-Razek, RS; El-Hefnawy, MH; El-Mesallamy, HO; Noureldein, MH | 1 |
El-Mas, MM; Helmy, MM; Helmy, MW | 1 |
Jia, WP; Wang, C; Zhang, ML; Zhong, Y; Zhu, YX | 1 |
Abd El-Haleim, EA; Bahgat, AK; Saleh, S | 1 |
Anabtawi, A; Miles, JM; Moriarty, PM | 1 |
Akbarieh, S; Gohari, S; Heydari, AH; Jafari, S; Jameshoorani, M; Sajedi, B; Yaghoubi, M | 1 |
Bhoi, B; Das, N; Giri, SR; Jain, MR; Kadam, S; Karmakar, E; Patel, H; Patel, PR; Ranvir, R; Rath, A; Rathod, R; Roy, SS; Swain, P; Trivedi, C; Wahli, W | 1 |
Assaf, N; El Sayed, NS; El-Shamarka, ME; Khadrawy, YA; Salem, NA | 1 |
Abdelrehim, AB; Ahmed, AF; Heeba, GH; Shehata, AHF | 1 |
Arima, T; Nakano, Y; Shimizu, A; Takahashi, H; Tobita, Y; Uchiyama, M | 1 |
Ali, AA; El-Raouf, OMA; El-Rhman, RHA; Gad, AM; Saad, EB | 1 |
Reviews
5 review(s) available for pioglitazone and fenofibrate
Article | Year |
---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary | 2020 |
Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.
Topics: Coronary Disease; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Prospective Studies; Randomized Controlled Trials as Topic; Stroke; Thiazolidinediones | 2007 |
Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metformin; Pioglitazone; Thiazolidinediones | 2017 |
Trials
8 trial(s) available for pioglitazone and fenofibrate
Article | Year |
---|---|
Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Double-Blind Method; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Metabolic Syndrome; Pioglitazone; Thiazolidinediones | 2005 |
Peroxisome proliferator-activated receptors increase human sebum production.
Topics: Adult; Cell Line, Transformed; Diabetes Mellitus; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Isotretinoin; Ligands; Lipogenesis; Male; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Sebaceous Glands; Sebum; Thiazolidinediones | 2006 |
Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men.
Topics: Adult; Arteries; Blood Pressure; Cell Adhesion Molecules; Cytokines; Double-Blind Method; Elasticity; Endothelium, Vascular; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation; Male; Middle Aged; Obesity; Pioglitazone; PPAR gamma; Pulsatile Flow; Thiazolidinediones | 2007 |
Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Topics: Adiponectin; AMP-Activated Protein Kinases; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Middle Aged; Multienzyme Complexes; Phosphorylation; Pioglitazone; PPAR alpha; PPAR gamma; Protein Serine-Threonine Kinases; Thiazolidinediones; Treatment Outcome | 2007 |
Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein β up-regulation.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Adult; Aged; Anthropometry; Biomarkers; Cardiovascular Diseases; CCAAT-Enhancer-Binding Protein-beta; Cell Count; Cell Membrane; Cytokines; Fenofibrate; Glucose Tolerance Test; Humans; Inflammation Mediators; Male; Middle Aged; Monocytes; Obesity; Pioglitazone; Recovery of Function; Risk Factors; Thiazolidinediones; Up-Regulation | 2012 |
Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue.
Topics: 3T3-L1 Cells; Adipocytes; Adult; Animals; Disease Models, Animal; Dyslipidemias; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Male; Mice; Obesity, Abdominal; Pioglitazone; Rats; Rats, Sprague-Dawley; RNA, Messenger; Serpins; Subcutaneous Fat, Abdominal; Thiazolidinediones; Treatment Outcome; Up-Regulation | 2014 |
Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis.
Topics: Aged; alpha-2-HS-Glycoprotein; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Inflammation; Lipids; Male; Middle Aged; Obesity; Pioglitazone; Signal Transduction; Sirtuin 1; Thiazolidinediones | 2015 |
Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Blood Pressure; Body Mass Index; Diet; Exercise; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones | 2017 |
Other Studies
55 other study(ies) available for pioglitazone and fenofibrate
Article | Year |
---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus w
Topics: Animals; Blood Volume; Body Fluids; Diabetes Mellitus, Type 2; Dogs; Haplorhini; Humans; Hypoglycemic Agents; Indoles; Pioglitazone; PPAR gamma; Rats; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones | 2009 |
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
Topics: Animals; Blood Glucose; Butyric Acid; Cell Line; Cholesterol; Cricetinae; Diabetes Mellitus, Type 2; Dogs; Drug Discovery; Dyslipidemias; Female; Humans; Indoles; Male; Mice; PPAR gamma; Rats; Structure-Activity Relationship | 2009 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.
Topics: Animals; Apolipoprotein A-I; Bezafibrate; Chlorocebus aethiops; Chromans; COS Cells; Fenofibrate; Gene Expression Regulation; Humans; Hypoglycemic Agents; Kinetics; Pioglitazone; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Transfection; Troglitazone; Tumor Cells, Cultured | 2000 |
PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.
Topics: Anti-Inflammatory Agents; Arteriosclerosis; CD4-Positive T-Lymphocytes; Cells, Cultured; Fenofibrate; Graft Survival; Heart Transplantation; Humans; Interferon-gamma; Interleukin-2; Lymphocyte Activation; Peroxisome Proliferators; Pioglitazone; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2002 |
Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis.
Topics: Adipose Tissue; Animals; Biomarkers; Blood Glucose; Eating; Energy Metabolism; Fenofibrate; Gene Expression; Glucose Tolerance Test; Glycated Hemoglobin; Homeostasis; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Lipids; Liver; Male; Obesity; Organ Size; Oxazines; Phenylpropionates; Pioglitazone; Rats; Rats, Mutant Strains; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Weight Gain | 2003 |
Effects of antihyperlipidemic agents on hepatic insulin sensitivity in perfused Goto-Kakizaki rat liver.
Topics: Animals; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Fenofibrate; Glycogen; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Liver; Male; Models, Animal; Perfusion; Pioglitazone; Rats; Thiazolidinediones | 2004 |
Effect of peroxisome proliferator-activated receptor activators on tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes.
Topics: Animals; Animals, Newborn; Cells, Cultured; Dose-Response Relationship, Drug; Fenofibrate; Lipopolysaccharides; Myocytes, Cardiac; NF-kappa B; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; RNA, Messenger; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2004 |
Differential regulation and properties of angiopoietin-like proteins 3 and 4.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-Like Protein 4; Angiopoietin-like Proteins; Angiopoietins; Animals; Blood Proteins; Fenofibrate; Food Deprivation; Gene Expression Regulation; Humans; Intercellular Signaling Peptides and Proteins; Lipoprotein Lipase; Male; Mice; Pioglitazone; PPAR alpha; PPAR delta; PPAR gamma; Protein Structure, Quaternary; Thiazoles; Thiazolidinediones | 2005 |
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Topics: Animals; Apolipoprotein E2; Apolipoproteins E; Atherosclerosis; Blood Glucose; Disease Models, Animal; Dyslipidemias; Female; Fenofibrate; Foam Cells; Homeostasis; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Macrophages; Mice; Mice, Mutant Strains; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2005 |
Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors.
Topics: Adiponectin; Alitretinoin; Animals; Caco-2 Cells; Cell Line; CHO Cells; Chromans; Cricetinae; DNA-Binding Proteins; Fenofibrate; HeLa Cells; Hepatocytes; Humans; Hydroxycholesterols; Liver X Receptors; Orphan Nuclear Receptors; Peroxisome Proliferator-Activated Receptors; Pioglitazone; PPAR alpha; Receptors, Adiponectin; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Retinoid X Receptors; Thiazolidinediones; Tretinoin; Troglitazone; Up-Regulation | 2005 |
[Are pioglitazone and fenofibrate effective for the prevention of cardiovascular disease in type 2 diabetes?].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Pioglitazone; Randomized Controlled Trials as Topic; Thiazolidinediones | 2006 |
High glucose-boosted inflammatory responses to lipopolysaccharide are suppressed by statin.
Topics: Chemokines; Cytokines; Fenofibrate; Glucose; Histiocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation Mediators; Lipopolysaccharides; Nitric Oxide; Nitric Oxide Synthase Type II; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Simvastatin; Thiazolidinediones; Time Factors; U937 Cells | 2007 |
Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Carrageenan; Disease Models, Animal; Dose-Response Relationship, Drug; Edema; Fenofibrate; Mice; Nociceptors; Pain; Pain Measurement; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Thiazolidinediones | 2007 |
Effects of combined PPARgamma and PPARalpha agonist therapy on reverse cholesterol transport in the Zucker diabetic fatty rat.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Fenofibrate; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Liver X Receptors; Male; Obesity; Orphan Nuclear Receptors; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Thiazolidinediones | 2008 |
Renal cytochrome P450 as a determinant of impaired natriuresis by PPAR-gamma ligands in ovariectomized obese rats.
Topics: Animals; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Dinoprostone; Disease Models, Animal; Edema; Epithelial Sodium Channels; Female; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Kidney; Ligands; Male; Natriuresis; Nitric Oxide Synthase; Obesity; Ovariectomy; Pioglitazone; PPAR gamma; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Zucker; Sodium; Thiazolidinediones | 2008 |
Combination therapy for treatment or prevention of atherosclerosis.
Topics: Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Humans; Hypertension; Male; Pioglitazone; Risk Assessment; Severity of Illness Index; Tetrazoles; Thiazolidinediones; Treatment Outcome | 2008 |
Small-interference RNA-mediated knock-down of aldehyde oxidase 1 in 3T3-L1 cells impairs adipogenesis and adiponectin release.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adiponectin; Aldehyde Oxidoreductases; Animals; Fenofibrate; Mice; Pioglitazone; RNA, Small Interfering; Thiazolidinediones | 2008 |
Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.
Topics: Adiponectin; Animals; Apolipoproteins C; Cholesterol; Cholesterol, HDL; Dogs; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Indicators and Reagents; Lipoprotein Lipase; Mice; Mice, Inbred C57BL; Nitriles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Transcriptional Activation; Triglycerides | 2008 |
A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Topics: Adolescent; Adult; Amides; Antihypertensive Agents; Area Under Curve; Chromatography, Liquid; Drug Interactions; Female; Fenofibrate; Fumarates; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Renin; Tandem Mass Spectrometry; Thiazolidinediones | 2008 |
Fenofibrate and pioglitazone do not ameliorate the altered vascular reactivity in aorta of isoproterenol-treated rats.
Topics: Adrenergic beta-Agonists; Animals; Aorta, Thoracic; Dose-Response Relationship, Drug; Endothelium, Vascular; Fenofibrate; Isoproterenol; Male; NG-Nitroarginine Methyl Ester; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Potassium Chloride; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Superoxide Dismutase; Thiazolidinediones; Vasoconstriction; Vasoconstrictor Agents; Vasodilation | 2008 |
BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner.
Topics: AMP-Activated Protein Kinases; Animals; Calcium; Cells, Cultured; Cytosol; Diabetes Mellitus; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Fenofibrate; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; KATP Channels; Mice; Mice, Inbred Strains; NADP; Obesity; Peroxisome Proliferator-Activated Receptors; Phosphatidylinositol 3-Kinases; Pioglitazone; Protein Kinase Inhibitors; Signal Transduction; Thiazolidinediones; Time Factors; Tissue Culture Techniques; Up-Regulation | 2009 |
Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Topics: Abdominal Fat; Adiposity; Animals; Body Weight; Dietary Fats; Disease Models, Animal; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lipid Metabolism; Male; Muscle, Skeletal; Obesity; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Zucker; Thiazolidinediones | 2009 |
On the mechanism for PPAR agonists to enhance ABCA1 gene expression.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Cell Line, Tumor; Fenofibrate; Fibroblasts; Gemfibrozil; Gene Expression Regulation; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pioglitazone; PPAR delta; PPAR gamma; Propionates; Thiazoles; Thiazolidinediones; Triazoles | 2009 |
Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm.
Topics: Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apolipoproteins E; Fenofibrate; Immunohistochemistry; Ligands; Macrophages; Male; Mice; Osteopontin; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Thiazolidinediones; Up-Regulation | 2010 |
CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes.
Topics: Adult; Chemokine CXCL11; Chemokine CXCL9; Cytokines; Female; Fenofibrate; Gemfibrozil; Graves Disease; Humans; Interferon-gamma; Male; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; T-Lymphocytes; Thiazolidinediones; Thyroid Gland; Thyroidectomy | 2010 |
Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats.
Topics: Adiposity; Animals; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collagen Type I; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Osteocalcin; Osteoporosis, Postmenopausal; Ovariectomy; Peptides; Pioglitazone; PPAR alpha; PPAR gamma; Random Allocation; Rats; Thiazolidinediones | 2012 |
β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy.
Topics: Cells, Cultured; Chemokine CCL2; Chemokine CXCL10; Fenofibrate; Fibroblasts; Graves Ophthalmopathy; Humans; Interferon-gamma; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2012 |
Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.
Topics: Adolescent; Adult; Aged; Female; Fenofibrate; Genome-Wide Association Study; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Male; Middle Aged; Muscle, Skeletal; Phenotype; Pioglitazone; PPAR alpha; PPAR gamma; Quantitative Trait Loci; Thiazolidinediones | 2012 |
Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.
Topics: Amino Acid Sequence; Animals; Cell Line; Cricetinae; Fenofibrate; Ligands; Molecular Sequence Data; Oxazoles; Peptides; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Thiophenes; Transcription, Genetic | 2012 |
Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.
Topics: Alkanesulfonates; Cells, Cultured; Fenofibrate; Hepatocytes; Humans; Oxazoles; Phenylpropionates; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Thiophenes | 2012 |
Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.
Topics: Animals; CD36 Antigens; Diet, High-Fat; Fenofibrate; Gene Expression Regulation; Glucose; Lipid Metabolism; Lipid Peroxidation; Mice; Mice, Knockout; Myocytes, Cardiac; Peroxisome Proliferator-Activated Receptors; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2012 |
An unusual cause of delayed puberty: Berardinelli- Seip syndrome.
Topics: Administration, Cutaneous; Adolescent; Atorvastatin; Combined Modality Therapy; Diet, Fat-Restricted; Drug Therapy, Combination; Estrogens; Exercise Therapy; Female; Fenofibrate; Fish Oils; Heptanoic Acids; Humans; Hypertension, Portal; Hypertriglyceridemia; Insulin; Insulin Resistance; Lipodystrophy, Congenital Generalized; Pioglitazone; Propranolol; Puberty, Delayed; Pyrroles; Thiazolidinediones; Treatment Outcome | 2012 |
Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Disease Models, Animal; Fenofibrate; Haloperidol; L-Lactate Dehydrogenase; Male; Mouth; Movement Disorders; Oxidative Stress; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Thiazolidinediones | 2013 |
Fenofibrate vs pioglitazone: Comparative study of the anti-arthritic potencies of PPAR-alpha and PPAR-gamma agonists in rat adjuvant-induced arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Body Weight; Bone and Bones; Bone Density; Fenofibrate; Male; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Inbred Lew; Thiazolidinediones | 2014 |
Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine.
Topics: Animals; Avoidance Learning; Caspase 3; Disease Models, Animal; Dopamine; Drug Administration Schedule; Drug Interactions; Exploratory Behavior; Fenofibrate; Male; MPTP Poisoning; Neuroprotective Agents; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Substantia Nigra; Swimming; Thiazolidinediones; Time Factors; Tyrosine 3-Monooxygenase | 2014 |
Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans.
Topics: Adult; Alcohol Drinking; Alcoholism; Alkanesulfonates; Animals; Bezafibrate; Brain; Female; Fenofibrate; Genome-Wide Association Study; Humans; Liver; Male; Mice; Phenylpropionates; Pioglitazone; Polymorphism, Single Nucleotide; PPAR alpha; PPAR gamma; Thiazoles; Thiazolidinediones | 2015 |
Effects of pioglitazone and fenofibrate co-administration on bone biomechanics and histomorphometry in ovariectomized rats.
Topics: Absorptiometry, Photon; Animals; Biomechanical Phenomena; Bone and Bones; Compressive Strength; Densitometry; Diaphyses; Female; Femur; Femur Neck; Fenofibrate; Lumbar Vertebrae; Ovariectomy; Pioglitazone; Rats, Sprague-Dawley; Thiazolidinediones; Tibia; Tomography, X-Ray Computed | 2015 |
Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Urea Nitrogen; Cisplatin; Creatinine; Fenofibrate; HEK293 Cells; Humans; Interleukin-6; Kidney; Kidney Function Tests; Male; Oxidative Stress; Pioglitazone; PPAR gamma; Protective Agents; Rats; Rats, Wistar; Thalidomide; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2015 |
Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver.
Topics: Animals; Diet, High-Fat; Fatty Liver; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Lipid Droplets; Liver; Male; Mice; Muscle Proteins; Obesity; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Proteins; Thiazolidinediones | 2016 |
Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
Topics: Adiponectin; Adipose Tissue; Animals; Blood Glucose; Body Weight; Dose-Response Relationship, Drug; Drug Interactions; Fenofibrate; Fructose; Gene Expression Regulation; Glutathione; Homeostasis; Insulin; Leptin; Liver; Male; Malondialdehyde; Non-alcoholic Fatty Liver Disease; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Thiazolidinediones; Triglycerides; Tumor Necrosis Factor-alpha | 2016 |
Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Biomarkers; Diet, High-Fat; Fenofibrate; Hep G2 Cells; Humans; Kupffer Cells; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Pioglitazone; PPAR alpha; Pyrroles; Tumor Necrosis Factor-alpha | 2018 |
Neuroprotective effect of PPAR alpha and gamma agonists in a mouse model of amyloidogenesis through modulation of the Wnt/beta catenin pathway via targeting alpha- and beta-secretases.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cognitive Dysfunction; Fenofibrate; Hippocampus; Infusions, Intraventricular; Male; Memory Disorders; Mice; Neuroprotective Agents; Peptide Fragments; Pioglitazone; PPAR alpha; PPAR gamma; Wnt Signaling Pathway | 2020 |
The impact of single and combined PPAR-α and PPAR-γ activation on the neurological outcomes following cerebral ischemia reperfusion.
Topics: Animals; Apoptosis; Brain; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Drug Therapy, Combination; Fenofibrate; Male; Neuroprotective Agents; Oxidative Stress; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Reperfusion Injury | 2020 |
Combination of Peroxisome Proliferator-Activated Receptor (PPAR) Alpha and Gamma Agonists Prevents Corneal Inflammation and Neovascularization in a Rat Alkali Burn Model.
Topics: Animals; Burns, Chemical; Corneal Injuries; Corneal Neovascularization; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Eye Burns; Fenofibrate; Fibrosis; Keratitis; Male; Ophthalmic Solutions; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; RNA, Messenger | 2020 |
Impact of peroxisome proliferator activated receptor agonist drugs in a model of nephrotoxicity in rats.
Topics: Animals; Apoptosis; Doxorubicin; Fenofibrate; Hypoglycemic Agents; Kidney; Male; NF-kappa B; Oxidative Stress; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Rats; Rats, Sprague-Dawley; Renal Insufficiency | 2023 |